Biotech Growth (Ordinary Share) BIOG

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV


Share Price


Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Biotech Growth (Ordinary Share) Price -4.70%
Biotech Growth (Ordinary Share) NAV -1.34%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement


Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 780.0 -7.5% 843.00 855.00
20 Jun

Discrete performance % over

Fund / BenchmarkJul '15
Jun '16
Jul '16
Jun '17
Jul '17
Jun '18
Biotech Growth (Ordinary Share) Price-30.3636.580.19
Biotech Growth (Ordinary Share) NAV-30.2845.46-2.72

Discrete performance over

Discrete Performance

Top 10 Holdings

Biogen Idec Inc., 12.47%
Celgene Corporation 9.67%
Amgen Inc 9.27%
Vertex Pharmaceuticals 8.58%
Regeneron Pharmaceuticals, Inc. 6.78%
Alnylam Pharmaceuticals, Inc. 4.19%
Illumina, Inc. 4.09%
Gilead Sciences Inc 3.99%
Puma Biotechnology Inc 3.29%
bluebird bio Inc 3.09%

Sectors weighting

Biotechnology 100.30%
Net Current Assets -0.30%

Regional weighting

North America Region 87.00%
Europe Developed ex-UK 10.00%
Other Countries 2.00%
UK 1.00%
Asia exc Japan 1.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 23 Jun 1997
  • Currency GBX
  • Domicile UK
  • Share Price 783.70
  • Share Type Ordinary Share
  • ISIN GB0000385517
  • Shares Issued (M) 56
  • Market Capital (£M) 435.55
  • Gross Assets (£M) 511.76
  • Net Assets (£M) 470.94
  • TER (%) 1.10
  • Last AGM 12 Jul 2017
  • Next AGM 12 Jul 2018
  • Last Annual Report Date 08 Jun 2017
  • Next due Report Date 31 Mar 2018
  • Next due Report Type A/R
  • Objective:

    To seek capital appreciation through investment in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis.

  • Management Group(s):

  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • Orbimed Capital LLC
  • Managed by:

  • Geoff Hsu Start: 19 May 2005
  • Richard Klemm Start: 19 May 2005
  • Management Contract & Fees:

    Under a new management, administration and company secretarial agreement with Frostrow Capital LLP, Frostrow will receive a periodic fee equal to 0.30% p.a. of the market capitalisation of the Company plus a fixed amount equal to £ 60,000 p.a. The Investment Manager received a fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may by terminated by either giving notice of not less than 12 months'. A performance fee is calculated quarterly by comparing the cumulative performance of the investment portfolio of the Company with the cumulative performance of the benchmark index since 30-Jun-05. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment manager receiving 15% and Manager 1.5% of the outperformance. At each quarterly calculation date any performance fee payable is based on the lower of: (i) the cumulative outperformance of the investment portfolio over the benchmark index as at the quarter end date; and (ii) the cumulative outperformance of the investment portfolio over the benchmark as at the corresponding quarter end date in the previous year. The Contract can be terminated on 12 months' notice.